Dr. John Glod, MD
Claim this profileNational Cancer Institute Pediatric Oncology Branch
Studies Brain Tumor
Studies Sarcoma
10 reported clinical trials
13 drugs studied
Area of expertise
1Brain Tumor
Stage IV
H3K27M positive
Stage III
2Sarcoma
Stage IV
HLA-A positive
MAGE-A4 positive
Affiliated Hospitals
Clinical Trials John Glod, MD is currently running
Dabrafenib + Trametinib + Hydroxychloroquine
for Brain Tumor
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with similar drugs that did not respond completely (progressive) or tumors that came back while receiving a similar agent (recurrent). Patients must also have specific genetic mutations including BRAF V600 mutations or BRAF fusion/duplication, with or without neurofibromatosis type 1. Neurofibromatosis type 1 is an inherited genetic condition that causes tumors to grow on nerve tissue. Hydroxychloroquine, works in different ways to stop the growth of tumor cells by killing the cells or stopping them from dividing. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving hydroxychloroquine with trametinib and/or dabrafenib may lower the chance of brain tumors growing or spreading compared to usual treatments.
Recruiting1 award Phase 1 & 216 criteria
Afamitresgene Autoleucel
for Sarcoma
This is a study to investigate the efficacy and safety of ADP-A2M4 in HLA-A\*02 eligible and MAGE-A4 positive subjects with metastatic or inoperable (advanced) Synovial Sarcoma (Cohort 1, 2 and 3 ) or MRCLS (Cohort 1) .
Recruiting1 award Phase 29 criteria
More about John Glod, MD
Clinical Trial Related8 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments John Glod, MD has experience with
- Ivosidenib
- Tipifarnib
- Selpercatinib
- Dabrafenib
- Trametinib
- Hydroxychloroquine
Breakdown of trials John Glod, MD has run
Brain Tumor
Sarcoma
Tumors
Osteosarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does John Glod, MD specialize in?
John Glod, MD focuses on Brain Tumor and Sarcoma. In particular, much of their work with Brain Tumor has involved Stage IV patients, or patients who are H3K27M positive.
Is John Glod, MD currently recruiting for clinical trials?
Yes, John Glod, MD is currently recruiting for 4 clinical trials in Bethesda Maryland. If you're interested in participating, you should apply.
Are there any treatments that John Glod, MD has studied deeply?
Yes, John Glod, MD has studied treatments such as Ivosidenib, Tipifarnib, Selpercatinib.
What is the best way to schedule an appointment with John Glod, MD?
Apply for one of the trials that John Glod, MD is conducting.
What is the office address of John Glod, MD?
The office of John Glod, MD is located at: National Cancer Institute Pediatric Oncology Branch, Bethesda, Maryland 20892 United States. This is the address for their practice at the National Cancer Institute Pediatric Oncology Branch.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.